At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase
Sesen Bio: Are the VISTA Results Up to Par?
I have recently received many questions on the micro-cap stock Sesen Bio (Nasdaq: SESN). This small company is attempting to make a big name for itself in the area of non-muscle invasive bladder … [Read more...] about Sesen Bio: Are the VISTA Results Up to Par?
You must be logged in to post a comment.